Premium
INHIBITION OF PHENYTOIN METABOLISM BY SULTHIAME IN EPILEPTIC PATIENTS
Author(s) -
HOUGHTON G.W.,
RICHENS A.
Publication year - 1974
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1974.tb00207.x
Subject(s) - phenytoin , metabolite , medicine , urinary system , pharmacology , urine , metabolism , epilepsy , psychiatry
1 Measurements have been made of steady state serum phenytoin concentration, serum half‐life of 14 C‐labelled phenytoin, and the urinary ratio of the major metabolite of phenytoin to the unchanged drug (p‐HPPH: DPH ratio) in epileptic patients on and off sulthiame therapy. 2 Starting sulthiame treatment produced an increase in serum phenytoin concentration, a prolongation of the half‐life and an increase in the p‐HPPH: DPH ratio. The total urinary output of phenytoin plus p‐HPPH was unaltered by sulthiame. 3 The results indicate that sulthiame or one of its metabolites inhibits the parahydroxylation of phenytoin by hepatic enzymes.